Nasim Shomali
Known title: DirectorCIK: 0001997065
Associated companies
Transaction History
| NTHI | ▲ Buy | Grant | 50,000 | — | 7/10/2026 | View on chart |
| NTHI | ▲ Buy | Grant | 50,000 | — | 7/10/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
NeOnc Sets FDA Meeting for NEO212; Roth Starts Coverage
NeOnc Technologies has scheduled an in-person FDA End-of-Phase 1 meeting for November 17 regarding its NEO212 candidate. This regulatory milestone provides a clear next step for the company's development timeline. Additionally, Roth Capital initiated coverage with a price target of $20, which is at the top of the current analyst range.
NeOnc Sets FDA Meeting for NEO212; Roth Starts Coverage. NeOnc Technologies has scheduled an in-person FDA End-of-Phase 1 meeting for November 17 regarding its NEO212 candidate. This regulatory milestone provides a clear next step for the company's development timeline. Additionally, Roth Capital initiated coverage with a price target of $20, which is at the top of the current analyst range.